Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tenax Therapeutics (TENX) with an Overweight rating and $20 price target The company is s developing TNX-103 in pulmonary hypertension associated with heart failure with preserved ejection fraction with the Phase 3 LEVEL readout expected in the second half of 2026, the analyst tells investors in a research note. The firm believes Tenax is “flying under the radar” despite having the potential win approval in a high unmet need indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX: